Please assess the completion status of the following clinical trial:

Trial Title: Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol.~* A male or female between, and including, 11 and 17 years of age at the time of the vaccination.~* Written informed assent/consent obtained from the subject/ from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of the subject's/the subject's parent's/guardian's knowledge.~* If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after vaccination.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.~* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y within the last five years.~* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W-135 and/or Y.~* Previous vaccination with tetanus toxoid within the last month.~* History of meningococcal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.~* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.~* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* History of chronic alcohol consumption and/or drug abuse.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects of 11-17 years of age who will receive GSK134612
- Group B (Type: ACTIVE_COMPARATOR): Subjects of 11-17 years of age who will receive MencevaxTM ACWY

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete